Christopher M. Holman

University of Missouri - Kansas City School of Law

Professor of Law

5100 Rockhill Road

Kansas City, MO 64110-2499

United States

  • University of Missouri - Kansas City School of Law

SCHOLARLY PAPERS

87

DOWNLOADS
Rank 6,963

SSRN RANKINGS

Top 6,963

in Total Papers Downloads

12,231

SSRN CITATIONS
Rank 27,355

SSRN RANKINGS

Top 27,355

in Total Papers Citations

24

CROSSREF CITATIONS

20

Scholarly Papers (87)

Actions:
Email selected abstracts
1.

The Impact of Human Gene Patents on Innovation and Access: A Survey of Human Gene Patent Litigation

UMKC Law Review, Vol. 76, p. 295, 2007
Number of pages: 67 Posted: 11 Feb 2008 Last Revised: 26 Mar 2013
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 1,813 (18,646)

Abstract:

Loading...

patents, gene, DNA, biologics, biotechnology, genetic testing, forensics, diagnostic testing, biomedical research, research tool, patent litigation, patent infringement

2.

Is Lilly Written Description a Paper Tiger?: A Comprehensive Assessment of the Impact of Eli Lilly and its Progeny in the Courts and Pto

Albany Law Journal of Science and Technology, Vol. 17, 2007
Number of pages: 93 Posted: 18 Oct 2006
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 727 (69,114)
Citation 4

Abstract:

Loading...

Eli Lilly, Enzo, Written Description, patent, biotechnology, lizardtech, Falkner, enablement, DNA, proteins

3.

Do Reverse Payment Settlements Violate the Antitrust Laws?

Santa Clara Computer and High Technology Law Journal, Vol. 23, p. 489, 2007
Number of pages: 99 Posted: 30 May 2007
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 582 (91,639)

Abstract:

Loading...

patent, hatch-waxman, generic drugs, antitrust, reverse payment, settlement, exclusion payment, pharmaceutical, paragraph IV certification

4.

Will Gene Patents Derail the Next-Generation of Genetic Technologies?: A Reassessment of the Evidence Suggests Not

80 UMKC L. REV. 563 (2012).
Number of pages: 44 Posted: 08 Feb 2012 Last Revised: 05 Apr 2013
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 445 (126,981)
Citation 4

Abstract:

Loading...

gene patents, genetic technology, genome sequencing, genetic testing, human genes, biotechnology, patents, patent law, gene patents, DNA patents, biotechnology, genetic testing, diagnostic testing, whole genome sequencing, patent thicket

5.

Gene Patents Under Fire: Weighing the Costs and Benefits

Christopher M. Holman, Gene Patents under Fire: Weighing the Costs and Benefits, book chapter in BIOTECHNOLOGY AND SOFTWARE PATENT LAW: A COMPARATIVE REVIEW ON NEW DEVELOPMENTS, edited by Emanuela Arezzo and Gustavo Ghidini, Edward Elgar Publishing (2011).
Number of pages: 28 Posted: 17 Nov 2010 Last Revised: 18 Feb 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 429 (132,543)

Abstract:

Loading...

Myriad, ACLU, patents, patent law, patent eligibility, patentable subject matter, gene patents, DNA patents, biotechnology, Section 101, BRCA, genetic testing, diagnostic testing

6.

Protein Similarity Score: A Simplified Version of the Blast Score as a Superior Alternative to Percent Identity for Claiming Genuses of Related Protein Sequences

Santa Clara Computer & High Technology Law Journal, Vol. 21, p. 55, 2004
Number of pages: 45 Posted: 01 Oct 2006
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 393 (146,615)

Abstract:

Loading...

biotechnology, BLAST, similarity, patents, written description, enablement, percent identity, similarity score, proteins, DNA, sequence

7.

Antibody Patents: Use of the Written Description and Enablement Requirements at the Patent & Trademark Office

Berkeley Technology Law Journal, Vol. 38, p. 1 (2023), WVU College of Law Research Paper No. 2022-005
Number of pages: 50 Posted: 10 Feb 2022 Last Revised: 01 Nov 2023
S. Sean Tu and Christopher M. Holman
West Virginia University College of Law and University of Missouri - Kansas City School of Law
Downloads 392 (147,083)
Citation 1

Abstract:

Loading...

patent, antibody, USPTO, PTO, written description, enablement, patent examiner, prosecution, litigation

8.

Bilski: Assessing the Impact of a Newly Invigorated Patent Eligibility Doctrine on the Pharmaceutical Industry and the Future of Personalized Medicine

Christopher M. Holman, Bilski: Assessing the Impact of a Newly Invigorated Patent-Eligibility Doctrine on the Pharmaceutical Industry and the Future of Personalized Medicine, 10 CURRENT TOPICS IN MEDICINAL CHEMISTRY 1937 (2010).
Number of pages: 13 Posted: 23 Jun 2009 Last Revised: 18 Feb 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 383 (150,866)

Abstract:

Loading...

Patents, Biotechnology, drugs, Bilski, patent eligibility, patentable subject matter, Labcorp, personalized medicine, diagnostics

9.

Copyright for Engineered DNA: An Idea Whose Time Has Come?

Christopher M. Holman, Copyright for Engineered DNA: An Idea Whose Time Has Come, 113 W. VA. L. REV. 699 (2011).
Number of pages: 40 Posted: 17 Nov 2010 Last Revised: 18 Feb 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 376 (154,090)
Citation 5

Abstract:

Loading...

Synthetic biology, biotechnology, intellectual property, copyright, patent, engineered genetic sequence, engineered DNA

10.

Will Gene Patents Impede Whole Genome Sequencing?: Deconstructing the Myth that 20% o the Human Genome Is Patented

Christopher M. Holman, Will Gene Patents Impede Whole Genome Sequencing?: Deconstructing the Myth That 20% of the Human Genome Is Patented, 2 IP THEORY 1 (2011).
Number of pages: 15 Posted: 25 Jul 2011 Last Revised: 18 Feb 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 326 (179,920)
Citation 2

Abstract:

Loading...

patents, patent law, gene patents, DNA patents, biotechnology, genetic testing, diagnostic testing, whole genome sequencing, patent thicket

11.

Antibody Claims and the Evolution of the Written Description / Enablement Requirement

IDEA 63(1):84 (2023)
Number of pages: 54 Posted: 07 Dec 2022 Last Revised: 14 Jan 2023
S. Sean Tu and Christopher M. Holman
West Virginia University College of Law and University of Missouri - Kansas City School of Law
Downloads 307 (191,684)
Citation 1

Abstract:

Loading...

antibody, patent, USPTO, patent examination, examiner, prosecution, written description, enablement, 35 USC 112(a)

12.

Biotechnology's Prescription for Patent Reform

Review of Intellectual Property Law, Vol. 5, p. 318, 2006
Number of pages: 31 Posted: 22 Sep 2006
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 303 (194,392)

Abstract:

Loading...

biotechnology, patent, H.R. 2795, patent reform, pharmaceutical, drug, reform, smith, congress, testimony, hearing

13.

Recent Developments Affecting the Enforcement, Procurement, and Licensing of Research Tool Patents

Joshua D. Sarnoff & Christopher M. Holman, Recent Developments Affecting the Enforcement, Procurement, and Licensing of Research Tool Patents, 23 BERKELEY TECH. L.J. 1299 (2008).
Number of pages: 68 Posted: 10 Apr 2008 Last Revised: 18 Feb 2015
Joshua D. Sarnoff and Christopher M. Holman
DePaul University College of Law and University of Missouri - Kansas City School of Law
Downloads 272 (217,374)
Citation 2

Abstract:

Loading...

patent, research tool, experimental use, regulatory approval, compulsory licensing, exceptions and limitations, licensing, enforcement, patentability

14.

In Defense of Secondary Pharmaceutical Patents: A Response to the UN's Guidelines for Pharmaceutical Patent Examination

Indiana Law Review, Forthcoming
Number of pages: 56 Posted: 04 Sep 2016
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 248 (238,096)
Citation 2

Abstract:

Loading...

Secondary Pharmaceutical Patents, Guidelines for Pharmaceutical Patent Examination, Patents, Pharmaceutical Patents, Drug Patents

15.

Learning from Litigation: What Can Lawsuits Teach Us About the Role of Human Gene Patents in Research and Innovation?

Kansas Journal of Law & Public Policy, Vol. 18, p. 215, 2009
Number of pages: 52 Posted: 01 Sep 2009 Last Revised: 30 Mar 2013
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 237 (248,968)

Abstract:

Loading...

patents, gene, DNA, biologics, biotechnology, genetic testing, forensics, diagnostic testing, biomedical research, research tool, patent litigation, patent infringement, patent thicket, anticommons, university patenting, gene patents, DNA micro-array

16.

Response to ‘Pervasive Sequence Patents Cover the Entire Human Genome’

Genome Medicine, Vol. 6, No. 14, 2014, George Mason Law & Economics Research Paper No. 14-07, San Diego Legal Studies Paper No. 14-148, Loyola-LA Legal Studies Paper No. 2014-19, Georgia State University College of Law, Legal Studies Research Paper No. 2014-16
Number of pages: 4 Posted: 01 Mar 2014 Last Revised: 14 May 2014
S. Sean Tu, Christopher M. Holman, Adam Mossoff, Ted M. Sichelman, Michael Risch, Jorge L. Contreras, Yaniv Heled, Gregory Dolin and Lee Petherbridge
West Virginia University College of Law, University of Missouri - Kansas City School of Law, George Mason University - Antonin Scalia Law School, University of San Diego School of Law, Villanova University Charles Widger School of Law, University of Utah - S.J. Quinney College of Law, Georgia State University College of Law, University of Baltimore - School of Law and Loyola Law School Los Angeles
Downloads 223 (263,929)
Citation 1

Abstract:

Loading...

gene patents, human genome, Myriad Genetics, patent claims, patent scope

17.

Are Engineered Genetic Sequences Copyrightable?: The U.S. Copyright Office Addresses a Matter of First Impression

35 Biotechnology Law Report 103 (2016)
Number of pages: 21 Posted: 02 Oct 2016
Christopher M. Holman, Claes Gustafsson and Andrew W. Torrance
University of Missouri - Kansas City School of Law, Independent and University of Kansas School of Law
Downloads 212 (276,607)
Citation 2

Abstract:

Loading...

Copyright, Copyright Office, Copyright Registration, DNA Copyright, Gene Copyright, Synthetic Biology, Biotechnology, Genetic Engineering

18.

Ajinomoto v. ITC, the Doctrine of Equivalents, and Biomolecule Claim Limitations at the Federal Circuit

Biotechnology Law Report, 2020
Number of pages: 25 Posted: 28 May 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 202 (289,295)

Abstract:

Loading...

Ajinomoto, patents, biotechnology, biomolecules, DNA, proteins, doctrine of equivalents, prosecution history estoppel

19.

Mayo, Myriad, and the Future of Innovation in Molecular Diagnostics and Personalized Medicine

Christopher M. Holman, Mayo, Myriad, and the Future of Innovation in Molecular Diagnostics and Personalized Medicine, 15 North Carolina Journal of Law and Technology 639 (2014).
Number of pages: 40 Posted: 17 Apr 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 201 (290,598)

Abstract:

Loading...

Mayo, Prometheus, gene patents, Myriad, patent eligibility, patentable subject matter, molecular diagnostics, personalized medicine

20.

Maintaining Incentives for Healthcare Innovation: A Response to the FTC's Report on Follow-On Biologics

Christopher M. Holman, Maintaining Incentives for Healthcare Innovation: A Response to the FTC's Report on Follow-On Biologics, 11 MINN. J.L. SCI. & TECH. 755 (2010).
Number of pages: 46 Posted: 02 Oct 2009 Last Revised: 18 Feb 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 201 (290,598)

Abstract:

Loading...

follow-on biologics, biosimilars, biogenerics, biologic drugs, Hatch-Waxman, FTC, patents, biotechnology, FDA, data exclusivity

21.

The Perils of Taking Property Too Far

Stanford Journal of Law, Science and Policy, Vol. 46, 2009
Number of pages: 19 Posted: 27 May 2009 Last Revised: 14 Nov 2012
Christopher Heaney, Julia Carbone, E. Richard Gold, Tania Bubela, Christopher M. Holman, Alessandra Colaianni, Tracy R. Lewis and Bob Cook-Deegan
Duke Institute for Genome Sciences & Policy, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Alberta - Faculty of Public Health, University of Missouri - Kansas City School of Law, affiliation not provided to SSRN, Duke University, Fuqua School of Business-Economics Group and Arizona State University (ASU) - School for the Future of Innovation in Society
Downloads 189 (307,308)

Abstract:

Loading...

biobank, biobanks, genetic testing, genomic testing, Canavan, Myriad, BRCA, research ethics, gene patents, genes, patents, ethics, business models, public health care, clinicial genetics

22.

Developments in Synthetic Biology are Altering the IP Imperatives of Biotechnology

17 Vanderbilt J. Ent. & Tech. L. 385 (2015).
Number of pages: 78 Posted: 27 Jun 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 177 (325,842)
Citation 2

Abstract:

Loading...

Patents, intellectual property, biotechnology, synthetic biology

23.

Patentability Standards for Follow-On Pharmaceutical Innovation

37 BIOTECHNOLOGY LAW REPORT 131 (2018)
Number of pages: 31 Posted: 31 Jul 2018 Last Revised: 06 May 2020
Christopher M. Holman, Timo Minssen and Eric M. Solovy
University of Missouri - Kansas City School of Law, University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law and Sidley Austin LLP
Downloads 166 (344,663)
Citation 2

Abstract:

Loading...

UNDP, Patentability Guidelines, Patent Examination, Pharmaceutical Patents, TRIPS Agreement

24.

The Role of Objective Indicia in Assessing the Nonobviousness of Pharmaceutical Inventions

37 Biotechnology Law Report 4 (2018)
Number of pages: 30 Posted: 08 Feb 2019
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 154 (367,050)

Abstract:

Loading...

nonobviousness, patent, pharmaceuticals, objective indicators, objective indicia, secondary considerations

25.

The Critical Role of Patents in the Development, Commercialization and Utilization of Innovative Genetic Diagnostic Tests and Personalized Medicine

Boston University journal of Science and Technology Law, Vol. 21, No. 2, 2015
Number of pages: 20 Posted: 12 Feb 2016
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 135 (407,725)

Abstract:

Loading...

patents, innovation, biotechnology, diagnostics, personalized medicine, Myriad, Mayo, Prometheus, genetics

26.

Congress Should Decline Ill-Advised Legislative Proposals Aimed at Evergreening of Pharmaceutical Patent Protection

The University of the Pacific Law Review, 2020
Number of pages: 30 Posted: 03 Jun 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 132 (414,990)

Abstract:

Loading...

patents, pharmaceuticals, drugs, legislation, evergreening, prduct hopping, patent thicketing

27.

Is the Chemical Genus Claim Really 'Dead' at the Federal Circuit?: Part II

41 BIOTECHNOLOGY LAW REPORT 58 (2022)
Number of pages: 30 Posted: 01 Mar 2023 Last Revised: 02 Mar 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 126 (430,065)

Abstract:

Loading...

patents, genus claims, pharmaceuticals, enablement, written description

28.

Patent Eligibility Post-Myriad: A Reinvigorated Judicial Wildcard of Uncertain Effect

George Washington Law Review, Vol. 82, No. 1796, 2014
Number of pages: 36 Posted: 20 Feb 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 126 (430,065)

Abstract:

Loading...

Patent eligibility, Prometheus, Mayo, Myriad, patentable subject matter

29.

Caught between a Rock and a Hard Place: How Limelight Compounds the Challenges Facing Biotechnology Innovators after Mayo and Myriad

Christopher M. Holman, Caught Between a Rock and a Hard Place: How Limelight Compounds the Challenges Facing Biotechnology Innovators After Mayo and Myriad, 33 BIOTECHNOLOGY LAW REPORT 135 (2014).
Number of pages: 4 Posted: 20 Feb 2015 Last Revised: 21 Feb 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 122 (440,846)

Abstract:

Loading...

Divided infringement, joint infringement, Muniauction, Limelight, Akamai, personalized medicine, genetic testing, molecular diagnostics, induced infringement, indirect patent infringement

30.

Bowman v. Monsanto Co.: A Bellwether for the Emerging Issue of Patentable Self-Replicating Technologies and Inadvertent Infringement

Missouri Law Review, Vol. 80, 2015
Number of pages: 59 Posted: 12 Feb 2016
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 117 (454,856)

Abstract:

Loading...

Patents, Self-replicating technology, DNA, biotechnology, self-replication, bowman, Monsanto, agriculture, seeds patents

31.

A Look at the Current Status of the CRISPR Patent Interferences Involving Broad Institute, University of California and University of Vienna, ToolGen, and Sigma-Aldrich

41 BIOTECHNOLOGY LAW REPORT 169 (2022)
Number of pages: 25 Posted: 08 Mar 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 113 (466,910)

Abstract:

Loading...

CRISPR, patent, interference

32.

The Enablement and Written Description Requirements Through the Lens of the Federal Circuit's Actions (As Opposed to Its Words)

41 BIOTECHNOLOGY LAW REPORT 219 (2022)
Number of pages: 26 Posted: 08 Mar 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 111 (473,207)

Abstract:

Loading...

patents, pharmaceuticals, 112(a), enablement, written description

33.

Amgen v. Sanofi: The Supreme Court Takes up the Enablement Requirement in the Context of Therapeutic Monoclonal Antibodies

41 BIOTECHNOLOGY LAW REPORT 269 (2022)
Number of pages: 21 Posted: 08 Mar 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 107 (485,703)

Abstract:

Loading...

patents, enablement, pharmaceuticals, Amgen, Sanofi, Supreme Court

34.

Charting the Contours of a Copyright Regime Optimized for Engineered Genetic Code

Oklahoma Law Review
Number of pages: 63 Posted: 04 Sep 2016
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 105 (492,449)
Citation 1

Abstract:

Loading...

Copyright, biotechnology, DNA, genetic code, synthetic biology

35.

Supreme Court Asked to Consider Role of Post-Filing Evidence in Assessing Obviousness of Pharmaceutical Inventions

34 Biotechnology L. Rep. 49 (2015).
Number of pages: 4 Posted: 27 Jun 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 102 (502,622)

Abstract:

Loading...

Patents, Nonobviousness, Pharmaceutical Patents, Drug Patents

36.

Is the Chemical Genus Claim Really 'Dead' at the Federal Circuit?: Part I

41 BIOTECHNOLOGY LAW REPORT 4 (2022).
Number of pages: 31 Posted: 01 Mar 2023 Last Revised: 04 Mar 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 97 (519,860)

Abstract:

Loading...

patent, enablement, written description, genus claims, chemical genus claims

37.

How Real is the Concern that Seed Patents Will Turn Farmers into Inadvertent Infringers?

Christopher M. Holman, How Real Is the Concern that Seed Patents Will Turn Farmers into Inadvertent Infringers?, 33 BIOTECHNOLOGY LAW REPORT 165 (2014).
Number of pages: 6 Posted: 20 Feb 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 90 (545,543)

Abstract:

Loading...

Bowman, Monsanto, genetically modified crops, agricultural biotechnology, inadvertent infringement, inadvertent patent infringement, patent exhaustion, seed patent

38.

Book Review: Patent Ethics: Prosecution, by David Hricik & Mercedes Meyers

The IP Law Book Review, Vol. 1, No. 1, pp 40-45, June 2010
Number of pages: 7 Posted: 09 Oct 2010
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 86 (561,028)

Abstract:

Loading...

Patents, Patent Law, Patent Prosecution, Patent Ethics, Legal Ethics, Professional Responsibility, PTO, Patent And Trademark Office, PTO Code of Professional Conduct, Model Rules of Professional Conduct, Model Code of Professional Responsibility

39.

Do Biotech Patent Lawsuits Really 'Overwhelmingly Lose?': A Response to Our Divided Patent System

34 Biotechnology L. Rep. 59 (2015).
Number of pages: 9 Posted: 27 Jun 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 81 (581,225)

Abstract:

Loading...

patents, biotechnology, patent litigation, patent empirical studies

40.

Misplaced Fears in the Battle Over Affordable Biotech Drugs

50 IDEA 565 (2010)
Number of pages: 27 Posted: 21 Mar 2015
David E. Adelman, David E. Adelman and Christopher M. Holman
University of Texas School of LawUniversity of Texas at Austin - Kay Bailey Hutchison Center for Energy, Law & Business and University of Missouri - Kansas City School of Law
Downloads 78 (594,051)

Abstract:

Loading...

follow-on biologics, biogenerics, biologics, patents, FDA, health care reform

41.

Patent Eligibility as a Policy Lever to Regulate the Patenting of Personalized Medicine

Christopher M. Holman, Patent Eligibility as a Policy Lever to Regulate the Patenting of Personalized Medicine, book chapter in PERSPECTIVES ON PATENTABLE SUBJECT MATTER, edited by Michael Abramowicz, F. Scott Kieff and James E. Daily, Cambridge University Press (2014).
Number of pages: 32 Posted: 20 Feb 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 77 (598,291)

Abstract:

Loading...

Patent eligibility, Prometheus, Mayo, Bilski, personalized medicine, diagnostics, diagnostic testing, molecular diagnostics, genetic testing, patentable subject matter

42.

Gilead Sciences Sued for Failing to Bring a Follow-on Version of Truvada to Market Sooner

Biotechnology Law Report, 2019
Number of pages: 15 Posted: 27 May 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 75 (607,240)

Abstract:

Loading...

patents, drugs, antitrust, product hopping, Gilead, Truvada

43.

Nuvo v. Dr. Reddy and the Patentability of Prophetic Pharmaceutical Inventions Based on Unexplained Inventive Insight

Biotechnology Law Report, 2019
Number of pages: 13 Posted: 27 May 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 75 (607,240)

Abstract:

Loading...

patents, patentability, drugs, written description requirement, inventive concept, Nuvo[comma separated]

44.

Unpredictability in Patent Law and Its Effect on Pharmaceutical Innovation

Missouri Law Review, Vol. 76, p. 645, 2011
Number of pages: 49 Posted: 21 Mar 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 69 (635,285)

Abstract:

Loading...

Patents, patent policy, pharmaceutical patents, drug patents, pharmaceutical innovation

45.

Helsinn v. Teva: Lingering Ambiguity after the U.S. Supreme Court Holds the AIA Did Not Alter the On-Sale Bar to Patentability

Biotechnology Law Report, 2019
Number of pages: 23 Posted: 27 May 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 62 (670,769)

Abstract:

Loading...

patents, biotechnology, pharamceuticals, on-sale bar, AIA, Helsinn

46.

The Renewable Fuel Standard Reimagined: Clearing a Path for Truly Advanced Biofuels

86 UMKC L. Rev. 805 (2018)
Number of pages: 50 Posted: 02 Jun 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 60 (681,359)

Abstract:

Loading...

renewable fuel standard, biofuels,

47.

Praxair v. Mallinckrodt: An Expanded Interpretation of the Printed Matter Doctrine with Important Implications for Biotechnology

37 BIOTECHNOLOGY LAW REPORT 188 (2018)
Number of pages: 17 Posted: 23 Oct 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 57 (697,684)

Abstract:

Loading...

Praxair, Printed Matter Doctrine, Patent Eligibility, Patent-Ability, Biotechnology

48.

Eli Lilly v. Teva: Generic Companies Infringe under Akamai IV in Case of Divided Infringement

36 BIOTECHNOLOGY LAW REPORT 31 (2017)
Number of pages: 7 Posted: 17 Aug 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 56 (703,392)

Abstract:

Loading...

patent, biotechnology, diagnostics, divided infringement, joint infringement, induced infringement, Akamai

49.

The Lilly Written Description Requirement: A Doctrinal Wildcard of Uncertain Effect

Research Handbook on Patent Law & Theory (2nd Edition), ISBN: 978-1-78536-411-2, Edward Elgar, 2019
Number of pages: 33 Posted: 02 Jun 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 54 (715,004)

Abstract:

Loading...

patent, biotechnology, written description requirement, Eli Lilly, Ariad, LWD

50.

Branded Drug Companies are Successfully Asserting the Doctrine of Equivalents in Hatch-Waxman Litigation

40 BIOTECHNOLOGY LAW REPORT 72 (2021)
Number of pages: 34 Posted: 25 Mar 2022
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 49 (745,854)

Abstract:

Loading...

pharmaceuticals, patents, Hatch-Waxman, doctrine of equivalents

51.

AbbVie Hopes to Maintain Humira Exclusivity Through Secondary Patents and Regulatory Barriers to Entry

36 BIOTECHNOLOGY LAW REPORT 9 (2017)
Number of pages: 8 Posted: 21 Apr 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 46 (765,465)

Abstract:

Loading...

secondry patents, biosimiars, interchangeables, biologics, Humira, FDA, citizen petition

52.

A Fractured International Response to CRISPR-Enabled Gene Editing of Agricultural Products

38 Biotechnology Law Report 3 (2019).
Number of pages: 54 Posted: 22 Apr 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 46 (765,465)

Abstract:

Loading...

CRISPR, gene editing

53.

The Role of Patent Eligibility in Policing Claim Scope

1 IP Theory 56 (2011)
Number of pages: 15 Posted: 21 Mar 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 46 (765,465)

Abstract:

Loading...

Bilski, patent eligibility, patentable subject matter

54.

Congress Considering Legislation Intended to Reverse the Recent Trend toward Devaluation of the U.S. Patent Right

37 BIOTECHNOLOGY LAW REPORT 243 (2018)
Number of pages: 12 Posted: 23 Oct 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 45 (772,303)

Abstract:

Loading...

patents, biotechnology, legislation, patent reform, patent devaluation

55.

Vanda v. West-Ward Pharmaceuticals: Good News for the Patent Eligibility of Diagnostics and Personalized Medicine, with Some Important Caveats

37 BIOTECHNOLOGY LAW REPORT 117 (2018)
Number of pages: 9 Posted: 23 Oct 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 45 (772,303)

Abstract:

Loading...

Vanda, Mayo, Patent Eligibility, Biotechnology, Diagnostic Test, Patent-Ability

56.

Congress Considering Legislation Aimed at Increasing Competition in Pharmaceuticals

Biotechnology Law Report, 2019
Number of pages: 15 Posted: 27 May 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 43 (786,349)

Abstract:

Loading...

patents, drugs, Congress, legislation, patent reform

57.

The Mayo Framework Is Bad for Your Health

23 George Mason Law Review 901 (2016)
Number of pages: 40 Posted: 02 Jun 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 41 (800,682)

Abstract:

Loading...

patent eligibility, patent, Mayo, biotechnology, diagnostics

58.

Government Involvement in Pharmaceutical Development Can Come Back to Haunt a Drug Company

40 BIOTECHNOLOGY LAW REPORT 4 (2021)
Number of pages: 26 Posted: 25 Mar 2022
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 40 (807,952)

Abstract:

Loading...

Pharmaceuticals, Bayh-Dole, Patents, March-in rights, Gilead

59.

The Broad Institute Scores Another Victory in Its Battle with the University of California over the Patenting of CRISPR

41 BIOTECHNOLOGY LAW REPORT 122 (2022)
Number of pages: 24 Posted: 08 Mar 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 39 (815,430)

Abstract:

Loading...

60.

A Biotechnology-Centric Look at Fee Shifting in Patent Litigation Post-Octane Fitness

36 BIOTECHNOLOGY LAW REPORT 81 (2017)
Number of pages: 4 Posted: 21 Oct 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 36 (838,852)

Abstract:

Loading...

Octane Fitness, Highmark, attorneys fees, attorney fee-shifting, patent litigation, biotechnology

61.

District Court’s Interpretation of Mayo in Arioso Diagnostics Does Not Bode Well for Patent Eligibility of Diagnostics and Personalized Medicine

33 BIOTECHNOLOGY LAW REPORT 46 (2014)
Number of pages: 3 Posted: 01 May 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 35 (846,959)

Abstract:

Loading...

patent eligibility, Mayo, Ariosa, diagnostics, personalized medicine, biotechnology

62.

The Federal Circuit Continues to Grapple with the Question of Patent Eligibility for Diagnostic Methods

40 BIOTECHNOLOGY LAW REPORT 151 (2021)
Number of pages: 37 Posted: 25 Mar 2022
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 34 (855,412)

Abstract:

Loading...

patents, diagnostics, Mayo. patent eligibility, Vanda, Ariosa

63.

The Supreme Court’s Devaluation of U.S. Patents

36 BIOTECHNOLOGY LAW REPORT 151 (2017)
Number of pages: 16 Posted: 21 Oct 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 34 (855,412)

Abstract:

Loading...

Sandoz, TC Heartland, Impression Products, patents, Supreme Court, biotechnology

64.

Recent PTO Guidance Charts a New Course Through the Patent Eligibility Quagmire

Biotechnology Law Report, 2019
Number of pages: 13 Posted: 27 May 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 34 (855,412)

Abstract:

Loading...

patent, patent eligibility, biotechnology, PTO guidance, Patent Office, PTO

65.

In re Huping Hu: Quantum Entanglement, Medical Innovation, and Patentability on the Scientific 'Fringe'

40 BIOTECHNOLOGY LAW REPORT 222 (2021)
Number of pages: 23 Posted: 25 Mar 2022
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 33 (863,877)

Abstract:

Loading...

quantum entanglement, utility requirement, patent examination, inoperative inventions, incredible inventions

66.

Trade Secret Law: An Increasingly Important Form of IP for Biotechnology

35 BIOTECHNOLOGY LAW REPORT 45 (2016)
Number of pages: 10 Posted: 27 Apr 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 31 (880,907)

Abstract:

Loading...

biotechnology, trade secret law, pharmaceuticals

67.

The Federal Circuit’s Ongoing Expansion of Obviousness-Type Double Patenting Creates Patent Prosecution Pitfalls

33 BIOTECHNOLOGY LAW REPORT 94 (2014)
Number of pages: 4 Posted: 27 Apr 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 30 (889,668)

Abstract:

Loading...

obviousness-type double patenting, patentability, pharmaceuticals, biotechnology

68.

FDA’s Efforts to Tame the 'Wild West' of Regenerative Medicine

36 BIOTECHNOLOGY LAW REPORT 217 (2017)
Number of pages: 6 Posted: 21 Oct 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 30 (889,668)

Abstract:

Loading...

regenerative medicine, FDA, regulation, stem cell treatments

69.

In Minerva v. Hologic, the U.S. Supreme Court Reins in the Equitable Doctrine of Assignor Estoppel

40 BIOTECHNOLOGY LAW REPORT 294 (2021)
Number of pages: 28 Posted: 25 Mar 2022
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 26 (926,570)

Abstract:

Loading...

patents, assignor estoppel, Minerva, Hologic, Supreme Court

70.

For Monoclonal Antibodies, Compliance with the Written Description Requirement Has Become a Moving Target

36 BIOTECHNOLOGY LAW REPORT 273 (2017)
Number of pages: 11 Posted: 06 Mar 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 23 (956,060)

Abstract:

Loading...

patents, monoclonals, antibodies, biotechnology, written description requirement, biologics

71.

Acorda Therapeutics and the Role of Blocking Patents in Assessing Objective Indicia of Nonobviousness in the Pharmaceutical Arts

37 BIOTECHNOLOGY LAW REPORT 305 (2018)
Number of pages: 9 Posted: 06 Mar 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 20 (987,221)

Abstract:

Loading...

patents, obviousness, secondary considerations, objecive indicia, pharmaceuticals, biotechnoogy, Acorda

72.

Enablement Invoked as a ‘Super-Written Description Requirement’ to Overturn $2.5 Billion Jury Verdict

37 BIOTECHNOLOGY LAW REPORT 63 (2018)
Number of pages: 5 Posted: 01 Mar 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 17 (1,019,644)

Abstract:

Loading...

patents, biotechnology, written description, enablement, Idenix

73.

Status Update: Implementation of Various Non-patent Aspects of the Biologics Price Competition and Innovation Act of 2009

34 BIOTECHNOLOGY LAW REPORT 189 (2015)
Number of pages: 8 Posted: 27 Apr 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 15 (1,041,460)

Abstract:

Loading...

BPCIA, biosimilars, FDA, biologics

74.

Cuozzo v. Lee: Supreme Court to Decide Its First Inter Partes Review Case

35 BIOTECHNOLOGY LAW REPORT 3 (2016)
Number of pages: 6 Posted: 27 Apr 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 14 (1,052,566)

Abstract:

Loading...

IPR, inter partes review, Cuozzo, patents, biotechnology

75.

In Myriad the Supreme Court Has, Once Again, Increased the Uncertainty of US Patent Law

32 BIOTECHNOLOGY LAW REPORT 289 (2013).
Number of pages: 5 Posted: 01 May 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 13 (1,063,401)

Abstract:

Loading...

patent, biotechnolgy, patent eligibility, Myriad

76.

The Medicines Company v. Hospira: When Does Outsourcing Drug Manufacture to a Third-Party Contractor Trigger an On-Sale Bar to Patentability?

35 BIOTECHNOLOGY LAW REPORT 129 (2016)
Number of pages: 8 Posted: 19 Apr 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 13 (1,063,401)

Abstract:

Loading...

Medicines Company, Hospira, patents, pharmaceuticals, on sale bar, biotechnology

77.

District Court's Interpretation of Mayo in Ariosa Diagnostics Does Not Bode Well for Patent Eligibility of Diagnostics and Personalized Medicine

33 BIOTECHNOLOGY LAW REPORT 46 (2014)
Number of pages: 3 Posted: 01 May 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 12 (1,074,315)

Abstract:

Loading...

Mayo, Ariosa, patent eligibility, diagnostic test

78.

Status Update: Implementation of the Patent Dispute Resolution Provisions of the Biologics Price Competition and Innovation Act

34 BIOTECHNOLOGY LAW REPORT 247 (2015)
Number of pages: 5 Posted: 27 Apr 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 12 (1,074,315)

Abstract:

Loading...

BPCIA, biosimilars, biologics, patent dance, patents

79.

The Biotechnology Industry Organization (BIO) and Pharmaceutical Research and Manufacturers of America (PhRMA) Seek En Banc Review of Ariosa Diagnostics v. Sequenom

34 BIOTECHNOLOGY LAW REPORT 169 (2015)
Number of pages: 2 Posted: 27 Apr 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 10 (1,096,268)

Abstract:

Loading...

patent eligibility, amicus, Mayo, Ariosa, BIO, PhRMA, biotechnology

80.

A Proliferation of Legislation Targeting Genetically Modified Crops

34 BIOTECHNOLOGY LAW REPORT 207 (2015)
Number of pages: 6 Posted: 27 Apr 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 10 (1,096,268)

Abstract:

Loading...

GMO, reguation, labeling, GMO labeling laws, EU

81.

In Life Technologies v. Promega the Supreme Court Leaves Unresolved Many Questions Regarding the Potential for Infringement under 35 U.S. 271(f)(1)

36 BIOTECHNOLOGY LAW REPORT 42 (2017)
Number of pages: 9 Posted: 21 Apr 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 10 (1,096,268)

Abstract:

Loading...

Life Technologies, Promega, patent, biotechnology, Supreme Court, 271(f)

82.

Mayo Update: Some Reason for Guarded Optimism

35 BIOTECHNOLOGY LAW REPORT 175 (2016)
Number of pages: 11 Posted: 19 Apr 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 10 (1,096,268)

Abstract:

Loading...

patents, patent eligibility, Mayo, biotechnology, diagnostics

83.

Two Recent U.S. Reports Identify Shortcomings in USDA’s Regulation of GE Crops

35 BIOTECHNOLOGY LAW REPORT 83 (2016)
Number of pages: 5 Posted: 27 Apr 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 9 (1,107,306)

Abstract:

Loading...

GME, GE, genetically engineered crops, regulation, agricultural biotechnology, corrdinated framework

84.

Setbacks in Implementing the Renewable Fuel Standard Lead to Calls for Reform

35 BIOTECHNOLOGY LAW REPORT 249 (2016)
Number of pages: 9 Posted: 19 Apr 2023
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 9 (1,107,306)

Abstract:

Loading...

biofuels, agricultural biotechnology, renewable fuel standard, renewable energy

85.

Trend in Human Gene Patent Litigation

Science 322:198-99 (2008)
Posted: 21 Mar 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law

Abstract:

Loading...

patent policy, patents, gene patents, patent litigation

86.

Patent Border Wars: Defining the Boundary between Scientific Discoveries and Patentable Inventions

Trends in Biotechnology, Vol. 25, pp. 539-543, 2007
Posted: 11 Feb 2008
Christopher M. Holman
University of Missouri - Kansas City School of Law

Abstract:

Loading...

patentable subject matter, research tools, genes, patents, gene patents, research tools

87.

Clearing a Path Through the Patent Thicket

Cell, Vol. 125, pp. 629-633, 2006
Posted: 18 Oct 2006 Last Revised: 17 May 2014
Christopher M. Holman
University of Missouri - Kansas City School of Law

Abstract:

Loading...

patents, biotechnology, patent thicket, research tools, research use, Bayh-Dole, upstream patents, junk patents, open source

Other Papers (4)

Total Downloads: 207
Actions:
Email selected abstracts
1.

Brief of Amici Curiae Interested Patent Law Professors in Support of Neither Party in Prometheus v. Mayo

Federal Circuit Court of Appeals, 2009 WL 462602
Number of pages: 28 Posted: 13 Nov 2009 Last Revised: 05 May 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 72

Abstract:

Loading...

Prometheus, Mayo, Bilski, patentable subject matter, patent eligibility, diagnostics, personalized medicine, biotechnology

2.

Brief of Amicus Curiae Law Professor Christopher M. Holman in Support of Neither Party in Ariad v. Eli Lilly

Federal Circuit Court of Appeals, 2009 WL 3711551
Number of pages: 42 Posted: 13 Nov 2009 Last Revised: 05 May 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 52

Abstract:

Loading...

Ariad, Eli Lilly, biotechnology, patent law, written description requirement, amicus

3.

On the Question: Is Copyright the Way to Gain Intellectual Property Protection for DNA Sequences?

33 Biotechnology Law Report 139, 2014
Number of pages: 2 Posted: 20 Sep 2014
Christopher M. Holman and Andrew W. Torrance
University of Missouri - Kansas City School of Law and University of Kansas School of Law
Downloads 46

Abstract:

Loading...

4.

Intellectual Property in the Age of Personal Genomics and Synthetic Biology

Christopher M. Holman, Intellectual Property in the Age of Personal Genomics and Synthetic Biology, 31 BIOTECHNOLOGY LAW REPORT 1 (2012).
Number of pages: 2 Posted: 17 Apr 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 37

Abstract:

Loading...

patents, intellectual property, biotechnology, genomics, synthetic biology, genetic testing, diagnostic testing